Amongst sufferers with MIBC, adjuvant Opdivo confirmed a continued profit in survival versus placebo.© inventory.adobe.com
Amongst sufferers with muscle-invasive bladder most cancers (MIBC), therapy with adjuvant Opdivo (nivolumab) continued to showcase a profit in disease-free survival (DFS) versus placebo, regardless of earlier therapy with neoadjuvant chemotherapy, in keeping with knowledge from an evaluation of the part 3 CheckMate-274 trial shared throughout the 2025 Genitourinary Cancers Symposium.
Glossary
Adjuvant: any extra most cancers therapy given after the first therapy.
Illness-free survival: the time after therapy when somebody is freed from indicators or signs of a illness.
Neoadjuvant: kind of most cancers therapy that’s given earlier than the principle therapy.
Total survival (OS): the typical size of time that sufferers are alive after being recognized with or beginning therapy for a illness.
Intravenous: means into the vein.
In all randomized sufferers with MIBC, the median DFS was 25.6 months with Opdivo (353 sufferers) versus 8.5 months with placebo (356 sufferers). The 24-month DFS charges within the respective arms have been 50.5% and 35.9%; at 36 months, these charges have been 46.8% and 32%. The median follow-up within the intention-to-treat (ITT) inhabitants was 36.1 months; within the MIBC inhabitants, the median follow-up was 34.5 months.
In sufferers with MIBC who beforehand acquired neoadjuvant chemotherapy, the median DFS with Opdivo (279 sufferers) was 19.6 months versus 8.3 months with placebo (281 sufferers). In sufferers with MIBC who had not beforehand acquired neoadjuvant chemotherapy, the median DFS was 25.9 months with Opdivo versus 13.7 months with placebo.
Knowledge from the interim total survival (OS) evaluation indicated that in all sufferers with MIBC, the median OS was not reached versus 39.9 months with placebo. The 24- and 36-month OS charges within the Opdivo arm have been 75.3% and 64.2%, respectively; within the placebo arm, these charges have been 66.2% and 53.7%, respectively.
In all randomized sufferers with MIBC and a tumor PD-L1 expression of not less than 1%, the median OS with Opdivo was once more not reached versus 37.6 months with placebo. These with MIBC who acquired prior neoadjuvant chemotherapy adjuvant Opdivo skilled a median OS of 55.2 months versus 40.2 months with placebo. These with MIBC with out prior neoadjuvant chemotherapy skilled a median OS that was not reached with Opdivo versus 37.7 months with placebo.
“The enhancements demonstrated in sufferers with MIBC present extra assist for adjuvant Opdivo as an ordinary of take care of high-risk muscle-invasive urothelial carcinoma [MIUC,] together with MIBC after radical surgical procedure, and no matter prior neoadjuvant chemotherapy,” Dr. Matthew I. Milowsky stated in a presentation of the information. “Of be aware, subcutaneous Opdivo was authorised for a number of indications, together with as adjuvant remedy for MIUC by the FDA late final yr, and may present another for sufferers throughout tumors.”
Milowsky is the George Gabriel and Frances Gable Villere Distinguished Professor of Bladder and Genitourinary Most cancers Analysis, co-leader of the College of North Carolina (UNC) Lineberger Scientific Analysis Program, part chief of Genitourinary Oncology and co-director of the Urologic Oncology Program at UNC College of Drugs in Chapel Hill.
The randomized, double-blind, multicenter, part 3 CheckMate-274 trial enrolled sufferers with ypT2 to ypT4a or ypN-positive MIUC who had neoadjuvant chemotherapy. These with pT3a to pT4a or pN-positive MIUC with out beforehand neoadjuvant chemotherapy who weren’t eligible for or refused adjuvant cisplatin chemotherapy have been additionally included. Sufferers underwent radical surgical procedure inside the previous 120 days and needed to be freed from illness inside 4 weeks of present process randomization.
Contributors have been randomized to obtain intravenous (IV) Opdivo or placebo at 240 mg each two weeks. They acquired adjuvant therapy for as much as 1 yr. Stratification elements included tumor PD-L1 standing (not less than 1% versus lower than 1% or indeterminate), prior receipt of neoadjuvant chemotherapy (sure versus no) or nodal standing.
The first finish factors of the trial have been DFS in all randomized sufferers and within the subset of sufferers with a tumor PD-L1 expression of not less than 1%. Knowledge confirmed that adjuvant Opdivo considerably improved DFS versus placebo in sufferers with high-risk MIUC put up–radical surgical procedure with or with out cisplatin-based neoadjuvant chemotherapy. Prolonged follow-up knowledge with a median of three years indicated that Opdivo continued to enhance DFS versus placebo in all randomized sufferers, these with PD-L1 expression of not less than 1% and people with MIBC. The primary report of OS outcomes confirmed that survival favored Opdivo versus placebo in all randomized sufferers and the subset of sufferers with a PD-L1 expression of not less than 1%.
For the post-hoc evaluation shared at convention, the important thing finish factors have been DFS in all randomized sufferers with MIBC and in these with MIBC in keeping with earlier neoadjuvant chemotherapy, and OS in all randomized sufferers with MIBC, these with MIBC and a tumor PD-L1 expression of 1% or greater and people with MIBC in keeping with prior neoadjuvant chemotherapy.
Milowsky stated that baseline scientific and demographic traits have been usually well-balanced between the arms. “[They] have been largely constant between the ITT and MIBC populations. About 80% of sufferers in CheckMate-274 had bladder tumor origin. Of these sufferers with MIBC, about 50% acquired prior neoadjuvant chemotherapy and about 40% had tumor PD-L1 positivity,” he stated.
Further efficacy knowledge indicated that in sufferers with MIBC who acquired prior neoadjuvant chemotherapy, the 24-month DFS charges with Opdivo and placebo have been 48.9% versus 33.2%, respectively; the 36-month charges have been 46.5% versus 28.9%, respectively. In sufferers with MIBC who had not acquired prior neoadjuvant chemotherapy, the 24-month DFS charges within the Opdivo and placebo arms have been 52.1% versus 38.8%, respectively; the 36-month DFS charges have been 46.9% versus 35.4%, respectively.
In all sufferers with MIBC and a tumor PD-L1 expression of not less than 1%, the 24-month OS fee with Opdivo was 82.6% versus 67.4% with placebo; the respective 36-month charges have been 71.8% and 52.0%. In these with MIBC and prior neoadjuvant chemotherapy, the 24-month OS charges with Opdivo and placebo have been 73.6% versus 63.2%, respectively; the 36-month charges have been 64.5% and 53.4%, respectively. In these with MIBC with out prior neoadjuvant chemotherapy, the 24-month OS fee with Opdivo was 77.1% versus 69.4% with placebo; the respective OS charges at 36 months have been 63.8% versus 53.9%.
“Security in sufferers with MIBC was in keeping with earlier knowledge in ITT sufferers, and no new security alerts have been recognized,” Milowsky concluded.
References
- “Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: extra efficacy outcomes together with total survival in sufferers with muscle-invasive bladder most cancers from CheckMate-274,” by Dr. Matthew I Milowsky, et al. Journal of Scientific Oncology.
- “FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection.” FDA. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-approves-nivolumab-and-hyaluronidase-nvhy-subcutaneous-injection
- “Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma,” by Dr. Dean F. Bajorin. The New England Journal of Drugs.
- “Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Expanded efficacy from CheckMate 274,” by Dr. Matthew D. Galsky. Journal of Scientific Oncology.
